IBBQ Quote, Financials, Valuation and Earnings

First Trust Health Care AlphaDEX Fund has a net margin of -- compared to Invesco Nasdaq Biotechnology ETF's net margin of --. Invesco Nasdaq Biotechnology ETF's return on equity of -- beat First Trust Health Care AlphaDEX Fund's return on equity of --.

Invesco Nasdaq Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Health Care AlphaDEX Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Nasdaq Biotechnology ETF has higher upside potential than First Trust Health Care AlphaDEX Fund, analysts believe Invesco Nasdaq Biotechnology ETF is more attractive than First Trust Health Care AlphaDEX Fund.

Invesco Nasdaq Biotechnology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Trust Health Care AlphaDEX Fund has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.906%.

Invesco Nasdaq Biotechnology ETF has a quarterly dividend of $0.06 per share corresponding to a yield of 1.09%. First Trust Health Care AlphaDEX Fund offers a yield of 0.41% to investors and pays a quarterly dividend of $0.09 per share. Invesco Nasdaq Biotechnology ETF pays -- of its earnings as a dividend. First Trust Health Care AlphaDEX Fund pays out -- of its earnings as a dividend.

Invesco Nasdaq Biotechnology ETF quarterly revenues are --, which are smaller than First Trust Health Care AlphaDEX Fund quarterly revenues of --. Invesco Nasdaq Biotechnology ETF's net income of -- is lower than First Trust Health Care AlphaDEX Fund's net income of --. Notably, Invesco Nasdaq Biotechnology ETF's price-to-earnings ratio is -- while First Trust Health Care AlphaDEX Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Nasdaq Biotechnology ETF is -- versus -- for First Trust Health Care AlphaDEX Fund. Usually stocks with elevated PS ratios are considered overvalued.

iShares Biotechnology ETF has a net margin of -- compared to Invesco Nasdaq Biotechnology ETF's net margin of --. Invesco Nasdaq Biotechnology ETF's return on equity of -- beat iShares Biotechnology ETF's return on equity of --.

Invesco Nasdaq Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Nasdaq Biotechnology ETF has higher upside potential than iShares Biotechnology ETF, analysts believe Invesco Nasdaq Biotechnology ETF is more attractive than iShares Biotechnology ETF.

Invesco Nasdaq Biotechnology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Biotechnology ETF has a beta of 0.740, suggesting its less volatile than the S&P 500 by 26.046%.

Invesco Nasdaq Biotechnology ETF has a quarterly dividend of $0.06 per share corresponding to a yield of 1.09%. iShares Biotechnology ETF offers a yield of 0.29% to investors and pays a quarterly dividend of $0.06 per share. Invesco Nasdaq Biotechnology ETF pays -- of its earnings as a dividend. iShares Biotechnology ETF pays out -- of its earnings as a dividend.

Invesco Nasdaq Biotechnology ETF quarterly revenues are --, which are smaller than iShares Biotechnology ETF quarterly revenues of --. Invesco Nasdaq Biotechnology ETF's net income of -- is lower than iShares Biotechnology ETF's net income of --. Notably, Invesco Nasdaq Biotechnology ETF's price-to-earnings ratio is -- while iShares Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Nasdaq Biotechnology ETF is -- versus -- for iShares Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.

iShares US Medical Devices ETF has a net margin of -- compared to Invesco Nasdaq Biotechnology ETF's net margin of --. Invesco Nasdaq Biotechnology ETF's return on equity of -- beat iShares US Medical Devices ETF's return on equity of --.

Invesco Nasdaq Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Medical Devices ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Nasdaq Biotechnology ETF has higher upside potential than iShares US Medical Devices ETF, analysts believe Invesco Nasdaq Biotechnology ETF is more attractive than iShares US Medical Devices ETF.

Invesco Nasdaq Biotechnology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares US Medical Devices ETF has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.601%.

Invesco Nasdaq Biotechnology ETF has a quarterly dividend of $0.06 per share corresponding to a yield of 1.09%. iShares US Medical Devices ETF offers a yield of 0.46% to investors and pays a quarterly dividend of $0.11 per share. Invesco Nasdaq Biotechnology ETF pays -- of its earnings as a dividend. iShares US Medical Devices ETF pays out -- of its earnings as a dividend.

Invesco Nasdaq Biotechnology ETF quarterly revenues are --, which are smaller than iShares US Medical Devices ETF quarterly revenues of --. Invesco Nasdaq Biotechnology ETF's net income of -- is lower than iShares US Medical Devices ETF's net income of --. Notably, Invesco Nasdaq Biotechnology ETF's price-to-earnings ratio is -- while iShares US Medical Devices ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Nasdaq Biotechnology ETF is -- versus -- for iShares US Medical Devices ETF. Usually stocks with elevated PS ratios are considered overvalued.